Saline irrigation for chronic rhinosinusitis
This review is one of six looking at the primary medical management options for patients with chronic rhinosinusitis.Chronic rhinosinusitis is common and is characterised by inflammation of the lining of the nose and paranasal sinuses leading to nasal blockage, nasal discharge, facial pressure/pain...
Saved in:
| Published in: | Cochrane database of systematic reviews Vol. 4; p. CD011995 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
England
26.04.2016
|
| Subjects: | |
| ISSN: | 1469-493X |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | This review is one of six looking at the primary medical management options for patients with chronic rhinosinusitis.Chronic rhinosinusitis is common and is characterised by inflammation of the lining of the nose and paranasal sinuses leading to nasal blockage, nasal discharge, facial pressure/pain and loss of sense of smell. The condition can occur with or without nasal polyps. Nasal saline irrigation is commonly used to improve patient symptoms.
To evaluate the effects of saline irrigation in patients with chronic rhinosinusitis.
The Cochrane ENT Information Specialist searched the ENT Trials Register; Central Register of Controlled Trials (CENTRAL 2015, Issue 9); MEDLINE; EMBASE; ClinicalTrials.gov; ICTRP and additional sources for published and unpublished trials. The date of the search was 30 October 2015.
Randomised controlled trials (RCTs) with a follow-up period of at least three months comparing saline delivered to the nose by any means (douche, irrigation, drops, spray or nebuliser) with (a) placebo, (b) no treatment or (c) other pharmacological interventions.
We used the standard methodological procedures expected by Cochrane. Our primary outcomes were disease-specific health-related quality of life (HRQL), patient-reported disease severity and the commonest adverse event - epistaxis. Secondary outcomes included general HRQL, endoscopic nasal polyp score, computerised tomography (CT) scan score and the adverse events of local irritation and discomfort. We used GRADE to assess the quality of the evidence for each outcome; this is indicated in italics.
We included two RCTs (116 adult participants). One compared large-volume (150 ml) hypertonic (2%) saline irrigation with usual treatment over a six-month period; the other compared 5 ml nebulised saline twice a day with intranasal corticosteroids, treating participants for three months and evaluating them on completion of treatment and three months later. Large-volume, hypertonic nasal saline versus usual care One trial included 76 adult participants (52 intervention, 24 control) with or without polyps.Disease-specific HRQL was reported using the Rhinosinusitis Disability Index (RSDI; 0 to 100, 100 = best quality of life). At the end of three months of treatment, patients in the saline group were better than those in the placebo group (mean difference (MD) 6.3 points, 95% confidence interval (CI) 0.89 to 11.71) and at six months there was a greater effect (MD 13.5 points, 95% CI 9.63 to 17.37). We assessed the evidence to be of low quality for the three months follow-up and very low quality for the six months follow-up. Patient-reported disease severity was evaluated using a "single-item sinus symptom severity assessment" but the range of scores is not stated, making it impossible for us to determine the meaning of the data presented.No adverse effects data were collected in the control group but 23% of participants in the saline group experienced side effects including epistaxis. General HRQL was measured using SF-12 (0 to 100, 100 = best quality of life). No difference was found after three months of treatment (low quality evidence) but at six months there was a small difference favouring the saline group, which may not be of clinical significance and has high uncertainty (MD 10.5 points, 95% CI 0.66 to 20.34) (very low quality evidence). Low-volume, nebulised saline versus intranasal corticosteroids One trial included 40 adult participants with polyps. Our primary outcome of disease-specific HRQL was not reported. At the end of treatment (three months) the patients who had intranasal corticosteroids had less severe symptoms (MD -13.50, 95% CI -14.44 to -12.56); this corresponds to a large effect size. We assessed the evidence to be of very low quality.
The two studies were very different in terms of included populations, interventions and comparisons and so it is therefore difficult to draw conclusions for practice. The evidence suggests that there is no benefit of a low-volume (5 ml) nebulised saline spray over intranasal steroids. There is some benefit of daily, large-volume (150 ml) saline irrigation with a hypertonic solution when compared with placebo, but the quality of the evidence is low for three months and very low for six months of treatment. |
|---|---|
| AbstractList | This review is one of six looking at the primary medical management options for patients with chronic rhinosinusitis.Chronic rhinosinusitis is common and is characterised by inflammation of the lining of the nose and paranasal sinuses leading to nasal blockage, nasal discharge, facial pressure/pain and loss of sense of smell. The condition can occur with or without nasal polyps. Nasal saline irrigation is commonly used to improve patient symptoms.
To evaluate the effects of saline irrigation in patients with chronic rhinosinusitis.
The Cochrane ENT Information Specialist searched the ENT Trials Register; Central Register of Controlled Trials (CENTRAL 2015, Issue 9); MEDLINE; EMBASE; ClinicalTrials.gov; ICTRP and additional sources for published and unpublished trials. The date of the search was 30 October 2015.
Randomised controlled trials (RCTs) with a follow-up period of at least three months comparing saline delivered to the nose by any means (douche, irrigation, drops, spray or nebuliser) with (a) placebo, (b) no treatment or (c) other pharmacological interventions.
We used the standard methodological procedures expected by Cochrane. Our primary outcomes were disease-specific health-related quality of life (HRQL), patient-reported disease severity and the commonest adverse event - epistaxis. Secondary outcomes included general HRQL, endoscopic nasal polyp score, computerised tomography (CT) scan score and the adverse events of local irritation and discomfort. We used GRADE to assess the quality of the evidence for each outcome; this is indicated in italics.
We included two RCTs (116 adult participants). One compared large-volume (150 ml) hypertonic (2%) saline irrigation with usual treatment over a six-month period; the other compared 5 ml nebulised saline twice a day with intranasal corticosteroids, treating participants for three months and evaluating them on completion of treatment and three months later. Large-volume, hypertonic nasal saline versus usual care One trial included 76 adult participants (52 intervention, 24 control) with or without polyps.Disease-specific HRQL was reported using the Rhinosinusitis Disability Index (RSDI; 0 to 100, 100 = best quality of life). At the end of three months of treatment, patients in the saline group were better than those in the placebo group (mean difference (MD) 6.3 points, 95% confidence interval (CI) 0.89 to 11.71) and at six months there was a greater effect (MD 13.5 points, 95% CI 9.63 to 17.37). We assessed the evidence to be of low quality for the three months follow-up and very low quality for the six months follow-up. Patient-reported disease severity was evaluated using a "single-item sinus symptom severity assessment" but the range of scores is not stated, making it impossible for us to determine the meaning of the data presented.No adverse effects data were collected in the control group but 23% of participants in the saline group experienced side effects including epistaxis. General HRQL was measured using SF-12 (0 to 100, 100 = best quality of life). No difference was found after three months of treatment (low quality evidence) but at six months there was a small difference favouring the saline group, which may not be of clinical significance and has high uncertainty (MD 10.5 points, 95% CI 0.66 to 20.34) (very low quality evidence). Low-volume, nebulised saline versus intranasal corticosteroids One trial included 40 adult participants with polyps. Our primary outcome of disease-specific HRQL was not reported. At the end of treatment (three months) the patients who had intranasal corticosteroids had less severe symptoms (MD -13.50, 95% CI -14.44 to -12.56); this corresponds to a large effect size. We assessed the evidence to be of very low quality.
The two studies were very different in terms of included populations, interventions and comparisons and so it is therefore difficult to draw conclusions for practice. The evidence suggests that there is no benefit of a low-volume (5 ml) nebulised saline spray over intranasal steroids. There is some benefit of daily, large-volume (150 ml) saline irrigation with a hypertonic solution when compared with placebo, but the quality of the evidence is low for three months and very low for six months of treatment. BACKGROUNDThis review is one of six looking at the primary medical management options for patients with chronic rhinosinusitis.Chronic rhinosinusitis is common and is characterised by inflammation of the lining of the nose and paranasal sinuses leading to nasal blockage, nasal discharge, facial pressure/pain and loss of sense of smell. The condition can occur with or without nasal polyps. Nasal saline irrigation is commonly used to improve patient symptoms.OBJECTIVESTo evaluate the effects of saline irrigation in patients with chronic rhinosinusitis.SEARCH METHODSThe Cochrane ENT Information Specialist searched the ENT Trials Register; Central Register of Controlled Trials (CENTRAL 2015, Issue 9); MEDLINE; EMBASE; ClinicalTrials.gov; ICTRP and additional sources for published and unpublished trials. The date of the search was 30 October 2015.SELECTION CRITERIARandomised controlled trials (RCTs) with a follow-up period of at least three months comparing saline delivered to the nose by any means (douche, irrigation, drops, spray or nebuliser) with (a) placebo, (b) no treatment or (c) other pharmacological interventions.DATA COLLECTION AND ANALYSISWe used the standard methodological procedures expected by Cochrane. Our primary outcomes were disease-specific health-related quality of life (HRQL), patient-reported disease severity and the commonest adverse event - epistaxis. Secondary outcomes included general HRQL, endoscopic nasal polyp score, computerised tomography (CT) scan score and the adverse events of local irritation and discomfort. We used GRADE to assess the quality of the evidence for each outcome; this is indicated in italics.MAIN RESULTSWe included two RCTs (116 adult participants). One compared large-volume (150 ml) hypertonic (2%) saline irrigation with usual treatment over a six-month period; the other compared 5 ml nebulised saline twice a day with intranasal corticosteroids, treating participants for three months and evaluating them on completion of treatment and three months later. Large-volume, hypertonic nasal saline versus usual care One trial included 76 adult participants (52 intervention, 24 control) with or without polyps.Disease-specific HRQL was reported using the Rhinosinusitis Disability Index (RSDI; 0 to 100, 100 = best quality of life). At the end of three months of treatment, patients in the saline group were better than those in the placebo group (mean difference (MD) 6.3 points, 95% confidence interval (CI) 0.89 to 11.71) and at six months there was a greater effect (MD 13.5 points, 95% CI 9.63 to 17.37). We assessed the evidence to be of low quality for the three months follow-up and very low quality for the six months follow-up. Patient-reported disease severity was evaluated using a "single-item sinus symptom severity assessment" but the range of scores is not stated, making it impossible for us to determine the meaning of the data presented.No adverse effects data were collected in the control group but 23% of participants in the saline group experienced side effects including epistaxis. General HRQL was measured using SF-12 (0 to 100, 100 = best quality of life). No difference was found after three months of treatment (low quality evidence) but at six months there was a small difference favouring the saline group, which may not be of clinical significance and has high uncertainty (MD 10.5 points, 95% CI 0.66 to 20.34) (very low quality evidence). Low-volume, nebulised saline versus intranasal corticosteroids One trial included 40 adult participants with polyps. Our primary outcome of disease-specific HRQL was not reported. At the end of treatment (three months) the patients who had intranasal corticosteroids had less severe symptoms (MD -13.50, 95% CI -14.44 to -12.56); this corresponds to a large effect size. We assessed the evidence to be of very low quality.AUTHORS' CONCLUSIONSThe two studies were very different in terms of included populations, interventions and comparisons and so it is therefore difficult to draw conclusions for practice. The evidence suggests that there is no benefit of a low-volume (5 ml) nebulised saline spray over intranasal steroids. There is some benefit of daily, large-volume (150 ml) saline irrigation with a hypertonic solution when compared with placebo, but the quality of the evidence is low for three months and very low for six months of treatment. |
| Author | Philpott, Carl Schilder, Anne G M Chong, Lee Yee Scadding, Glenis Hopkins, Claire Head, Karen Burton, Martin J Glew, Simon |
| Author_xml | – sequence: 1 givenname: Lee Yee surname: Chong fullname: Chong, Lee Yee organization: UK Cochrane Centre, Oxford, UK – sequence: 2 givenname: Karen surname: Head fullname: Head, Karen – sequence: 3 givenname: Claire surname: Hopkins fullname: Hopkins, Claire – sequence: 4 givenname: Carl surname: Philpott fullname: Philpott, Carl – sequence: 5 givenname: Simon surname: Glew fullname: Glew, Simon – sequence: 6 givenname: Glenis surname: Scadding fullname: Scadding, Glenis – sequence: 7 givenname: Martin J surname: Burton fullname: Burton, Martin J – sequence: 8 givenname: Anne G M surname: Schilder fullname: Schilder, Anne G M |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27115216$$D View this record in MEDLINE/PubMed |
| BookMark | eNo1j0tLxDAYRYMozkP_wtClC1vzpXkupT5hwIUK7kraJk6kTWrSLvz3FhwXl7u4hwtng0598AahHeACMCY3QDkDyWRR3WEApVgxzg05QetlUDlV5ccKbVL6wrhUAPIcrYgAYAT4Gl2_6t55k7kY3aeeXPCZDTFrDzF412bx4HxIzs_JTS5doDOr-2Quj71F7w_3b9VTvn95fK5u93lLRUnytu14w5UmwDRWmMMSJiUpobTKCMGFBUUaQmWneCml7qziUhtQiwQVlmzR1d_vGMP3bNJUDy61pu-1N2FONQjJGeGY0QXdHdG5GUxXj9ENOv7U_4bkF0EPUmY |
| CitedBy_id | crossref_primary_10_1111_resp_13026 crossref_primary_10_1007_s40136_018_0211_7 crossref_primary_10_3390_jcm8010064 crossref_primary_10_2147_IDR_S381715 crossref_primary_10_1038_s41572_020_00218_1 crossref_primary_10_1007_s00405_019_05324_9 crossref_primary_10_1007_s12070_023_03990_0 crossref_primary_10_1007_s12070_023_03525_7 crossref_primary_10_7717_peerj_7000 crossref_primary_10_1002_lary_30155 crossref_primary_10_1007_s12070_021_02749_9 crossref_primary_10_1007_s40136_019_00232_2 crossref_primary_10_1177_2473974X221105277 crossref_primary_10_1136_dtb_2018_000023 crossref_primary_10_1007_s13346_023_01455_z crossref_primary_10_3389_fped_2020_00379 crossref_primary_10_1055_a_2246_2793 crossref_primary_10_3389_fnmol_2022_1019877 crossref_primary_10_3389_fpubh_2023_1145669 crossref_primary_10_1007_s00106_018_0513_6 crossref_primary_10_1007_s00894_022_05213_9 crossref_primary_10_1007_s00405_024_08937_x crossref_primary_10_1007_s42399_019_0050_y crossref_primary_10_1007_s00405_019_05752_7 crossref_primary_10_1080_17425247_2025_2539958 crossref_primary_10_3390_md20050330 crossref_primary_10_3390_ijerph14050516 crossref_primary_10_1177_01455613251342857 crossref_primary_10_3389_fped_2019_00459 crossref_primary_10_1007_s40521_024_00362_z crossref_primary_10_1080_1744666X_2023_2233700 crossref_primary_10_3399_BJGPO_2024_0307 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7U8 7X8 C1K JXQ |
| DOI | 10.1002/14651858.CD011995.pub2 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed TOXLINE MEDLINE - Academic Environmental Sciences and Pollution Management Toxline |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) TOXLINE MEDLINE - Academic Environmental Sciences and Pollution Management |
| DatabaseTitleList | MEDLINE TOXLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1469-493X |
| EndPage | CD011995 |
| ExternalDocumentID | 27115216 |
| Genre | Meta-Analysis Research Support, Non-U.S. Gov't Systematic Review Journal Article |
| GrantInformation_xml | – fundername: Department of Health grantid: NIHR-RP-011-045 |
| GroupedDBID | --- 53G 5GY 7PX 9HA ABJNI ACGFO ACGFS AENEX ALMA_UNASSIGNED_HOLDINGS ALUQN AYR CGR CUY CVF D7G ECM EIF HYE NPM OEC OK1 P2P RWY WOW ZYTZH 7U8 7X8 C1K JXQ |
| ID | FETCH-LOGICAL-c4732-ccd6b69a215a090619065882313f9e7767f192b248d96388adf968ae1985847f2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 38 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000375927100046&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| IngestDate | Wed Oct 01 14:02:07 EDT 2025 Sat Jun 28 01:34:48 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4732-ccd6b69a215a090619065882313f9e7767f192b248d96388adf968ae1985847f2 |
| Notes | SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Review-1 ObjectType-Article-3 ObjectType-Undefined-4 |
| OpenAccessLink | https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011995.pub2/pdf/full |
| PMID | 27115216 |
| PQID | 1786526054 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1786526054 pubmed_primary_27115216 |
| PublicationCentury | 2000 |
| PublicationDate | 2016-04-26 |
| PublicationDateYYYYMMDD | 2016-04-26 |
| PublicationDate_xml | – month: 04 year: 2016 text: 2016-04-26 day: 26 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Cochrane database of systematic reviews |
| PublicationTitleAlternate | Cochrane Database Syst Rev |
| PublicationYear | 2016 |
| SSID | ssj0039118 |
| Score | 2.4757574 |
| SecondaryResourceType | review_article |
| Snippet | This review is one of six looking at the primary medical management options for patients with chronic rhinosinusitis.Chronic rhinosinusitis is common and is... BACKGROUNDThis review is one of six looking at the primary medical management options for patients with chronic rhinosinusitis.Chronic rhinosinusitis is common... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | CD011995 |
| SubjectTerms | Administration, Intranasal Adrenal Cortex Hormones - administration & dosage Adult Chronic Disease Humans Hypertonic Solutions - administration & dosage Nasal Polyps - drug therapy Nasal Sprays Quality of Life Randomized Controlled Trials as Topic Rhinitis - drug therapy Sinusitis - drug therapy Sodium Chloride - administration & dosage Therapeutic Irrigation - methods Time Factors |
| Title | Saline irrigation for chronic rhinosinusitis |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/27115216 https://www.proquest.com/docview/1786526054 |
| Volume | 4 |
| WOSCitedRecordID | wos000375927100046&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEB7Uinjx_agvIng0Ntmkm9mTSLV4sKXgg97CZh_YS1IT6u93J0n1JAhecgsks_P4dr7dbwCu6O6kDKXwg4xzP-bG5UFrjC8wQJVEqHXd73h7SsZjnE7FpG24Ve2xymVOrBO1LhT1yHthgrxP4Du-nX_4NDWK2NV2hMYqdCIHZcirk-k3ixC5QMblreCA9UKa-419vBnck9KZ6NMvs9-hZV1ihtv__bgd2GrBpXfXeMMurJh8DzZGLX2-D9fPklClNyvLWlmjyD2HWT3VCOR65fssL6pZvqBzXNUBvA4fXgaPfjsuwVdxEjFfKc0zLqQr4jIQrk4LghdE80VWGFLtsQ7OZSxGTVGHUlvBUZpQIHGllh3CWl7k5hg8FmbMRsJmGrPYWC1RChQqNoFx2ydtu3C5tEPq3JE4BpmbYlGlP5bowlFjzHTe6GakLAkJLfCTP7x9CpsOmnDibRg_g451wWjOYV19OgOUF_U6u-d4MvoCCkWx5Q |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Saline+irrigation+for+chronic+rhinosinusitis&rft.jtitle=Cochrane+database+of+systematic+reviews&rft.au=Chong%2C+Lee+Yee&rft.au=Head%2C+Karen&rft.au=Hopkins%2C+Claire&rft.au=Philpott%2C+Carl&rft.date=2016-04-26&rft.eissn=1469-493X&rft.volume=4&rft.spage=CD011995&rft.epage=CD011995&rft_id=info:doi/10.1002%2F14651858.CD011995.pub2&rft.externalDBID=NO_FULL_TEXT |